AU2002317482B2 - 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors - Google Patents

5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors Download PDF

Info

Publication number
AU2002317482B2
AU2002317482B2 AU2002317482A AU2002317482A AU2002317482B2 AU 2002317482 B2 AU2002317482 B2 AU 2002317482B2 AU 2002317482 A AU2002317482 A AU 2002317482A AU 2002317482 A AU2002317482 A AU 2002317482A AU 2002317482 B2 AU2002317482 B2 AU 2002317482B2
Authority
AU
Australia
Prior art keywords
use according
disease
compounds
medicaments
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002317482A
Other languages
English (en)
Other versions
AU2002317482A1 (en
Inventor
Maria Assunta Di Cesare
Patrizia Minetti
Gilberto Spadoni
Giorgio Tarzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2002317482A1 publication Critical patent/AU2002317482A1/en
Application granted granted Critical
Publication of AU2002317482B2 publication Critical patent/AU2002317482B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AU2002317482A 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors Ceased AU2002317482B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM01A000356 2001-06-21
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
PCT/IT2002/000398 WO2003000252A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors

Publications (2)

Publication Number Publication Date
AU2002317482A1 AU2002317482A1 (en) 2003-06-19
AU2002317482B2 true AU2002317482B2 (en) 2007-08-16

Family

ID=11455609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317482A Ceased AU2002317482B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors

Country Status (21)

Country Link
US (1) US7098233B2 (enExample)
EP (1) EP1404317B1 (enExample)
JP (2) JP4683839B2 (enExample)
KR (1) KR100885308B1 (enExample)
CN (1) CN100482223C (enExample)
AT (1) ATE416767T1 (enExample)
AU (1) AU2002317482B2 (enExample)
BR (1) BR0210538A (enExample)
CA (1) CA2455296C (enExample)
CY (1) CY1108879T1 (enExample)
CZ (1) CZ20033314A3 (enExample)
DE (1) DE60230270D1 (enExample)
DK (1) DK1404317T3 (enExample)
ES (1) ES2319107T3 (enExample)
HU (1) HUP0400250A3 (enExample)
IT (1) ITRM20010356A1 (enExample)
MX (1) MXPA03011510A (enExample)
PL (1) PL367618A1 (enExample)
PT (1) PT1404317E (enExample)
SK (1) SK287828B6 (enExample)
WO (1) WO2003000252A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1497266E (pt) * 2002-03-27 2008-09-10 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
JPWO2005079845A1 (ja) 2004-02-20 2007-08-02 アステラス製薬株式会社 片頭痛予防薬
JP4998258B2 (ja) * 2005-02-08 2012-08-15 アステラス製薬株式会社 過敏性腸症候群の治療薬
ES2371106T3 (es) 2005-08-08 2011-12-27 Astellas Pharma Inc. Derivado de acilguanidina o sal del mismo.
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
EP1988075B1 (en) * 2006-02-20 2012-01-25 Astellas Pharma Inc. Pyrrole derivative or salt thereof
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
US20090093513A1 (en) * 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2648474C2 (ru) * 2011-08-05 2018-03-26 Сукампо Аг Способ лечения шизофрении
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
US9370662B2 (en) 2013-12-19 2016-06-21 Backbeat Medical, Inc. Methods and systems for controlling blood pressure by controlling atrial pressure
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
US12083116B2 (en) * 2018-06-21 2024-09-10 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
JP7655943B2 (ja) 2020-05-08 2025-04-02 サイレラ インコーポレイテッド 新規な組成物および医薬組成物
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
WO2022061196A1 (en) * 2020-09-18 2022-03-24 Mydecine Innovations Group Inc. Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
WO2023018480A1 (en) * 2021-08-09 2023-02-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective psychedelic compounds
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
CN114573578B (zh) * 2022-02-16 2023-11-17 烟台宁远药业有限公司 一种烷基取代氮杂吲哚的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034242A1 (en) * 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
FR2315277A1 (fr) * 1975-06-25 1977-01-21 Anvar Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent
US4428877A (en) * 1978-07-12 1984-01-31 Richter Gedeon Vegyeszeti Gyar Rt. Cis-10-bromo-E-homoeburnanes
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
ATE296801T1 (de) * 1996-06-28 2005-06-15 Meiji Seika Kaisha Tetrahydrobezindol derivate
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
ES2291024T4 (es) * 1999-04-21 2009-03-01 Nps Allelix Corp. Compuestos de piperidina-indol con afinidad con 5-ht6.
EP1204662B1 (en) 1999-08-12 2004-06-02 NPS Allelix Corp. Azaindoles having serotonin receptor affinity
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034242A1 (en) * 1998-12-11 2000-06-15 Virginia Commonwealth University Selective 5-ht6 receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Medicinal Chemistry Reseach (2000) 4(10) pp 230-42 *

Also Published As

Publication number Publication date
CA2455296A1 (en) 2003-01-03
EP1404317A1 (en) 2004-04-07
JP2004534816A (ja) 2004-11-18
SK287828B6 (sk) 2011-11-04
ES2319107T3 (es) 2009-05-04
JP4683839B2 (ja) 2011-05-18
HUP0400250A2 (hu) 2004-08-30
CZ20033314A3 (cs) 2004-08-18
HUP0400250A3 (en) 2008-03-28
KR20040032113A (ko) 2004-04-14
SK382004A3 (en) 2004-05-04
DE60230270D1 (de) 2009-01-22
MXPA03011510A (es) 2004-03-18
CN1535146A (zh) 2004-10-06
WO2003000252A1 (en) 2003-01-03
CA2455296C (en) 2010-08-17
DK1404317T3 (da) 2009-02-23
ATE416767T1 (de) 2008-12-15
ITRM20010356A1 (it) 2002-12-23
EP1404317B1 (en) 2008-12-10
US7098233B2 (en) 2006-08-29
PL367618A1 (en) 2005-03-07
PT1404317E (pt) 2009-02-23
HK1068792A1 (zh) 2005-05-06
KR100885308B1 (ko) 2009-02-24
CN100482223C (zh) 2009-04-29
ITRM20010356A0 (it) 2001-06-21
CY1108879T1 (el) 2014-07-02
BR0210538A (pt) 2004-06-22
US20040235899A1 (en) 2004-11-25
JP2011016835A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
AU2002317482B2 (en) 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
AU2002317482A1 (en) 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
Thompson et al. Synthesis and pharmacological evaluation of a series of dibenzo [a, d] cycloalkenimines as N-methyl-D-aspartate antagonists
WO2005047286A1 (ja) スピロ複素環化合物
MXPA04011331A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6.
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
MXPA01005905A (es) Ligandos selectivos de receptores de 5-ht6.
MXPA06001229A (es) Derivados de 1-sulfonilindol, su preparacion y su uso como ligandos de 5-ht6.
JP2017532377A (ja) インドリノン化合物及びその使用
AU2009330131A1 (en) Compounds and methods for the treatment of pain and other diseases
FR2930249A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5575663B2 (ja) 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
MXPA06005103A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de 5-hidroxitriptamina-6.
CN109641877A (zh) 结合5-ht7血清素受体的经咪唑基取代的吲哚衍生物及其药物组合物
BRPI0619126A2 (pt) derivados espirocìclicos, composição farmacêutica e usos dos mesmos
JP5690594B2 (ja) ３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
WO2017183723A1 (ja) Ｋｃｎｑ２～５チャネル活性化剤
CN104870451B (zh) 二氢‑吡啶并噁嗪衍生物的固体形式
WO2010040315A1 (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂的应用
JP2009545555A (ja) 置換インダニルスルホンアミド化合物、それらの調製、および薬剤としての使用
JPH08151366A (ja) １−ヒドロキシインドール誘導体
TW200819426A (en) Novel indane compounds
HK1068792B (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
TW379220B (en) Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant
TW200800888A (en) Substituted propylamine derivatives and methods of their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired